"One tube of blood" liquid biopsy technology for detecting cancer In the following studies, scientists invented liquid biopsy technology to detect fragmented DNA (ctDNA) in tumor cells that died in human blood. By blood sampling, tumor information of the whole body can be detected to achieve "one tube of blood." "Detecting cancer is very suitable for early diagnosis and precision medicine of cancer. Liquid biopsy has also become the hottest technology in cancer precision medicine . Circulating tumor DNA (ctDNA) high-throughput sequencing technology is one of the most promising liquid biopsies. It only needs to collect venous blood like liver and kidney function, and can accurately measure the tumor gene information of the whole body. Based on these tumor gene information, it can guide the selection of anti-tumor drugs, evaluation of efficacy, prognosis judgment, and even early detection and early stage. diagnosis. However, in practical applications, because the plasma ctDNA content is extremely low, the detection is very difficult, and the background noise of the second generation sequencing is very high. The conventional database construction method will completely overwhelm the tumor signal in the background noise. The ctDNA content is extremely low, the signal-to-noise ratio of the sequencing result is very low, and the systematic error of the sequencing platform is the three major challenges of the sequencing method of ctDNA. The new technology overcomes the three major problems of ctDNA detection and won the B round of financing of 40 million US dollars. According to a report by the well-known media in the US, GenomeWeb, on June 1, cancer diagnostics company Accuragen Holdings Limited announced the completion of a $40 million Series B round of financing, its core technology, Firefly? The technology has well overcome the challenges of ctDNA detection. This round of financing was jointly led by Ankeji A-round investor Fang Decheng Capital and Jiachen Capital, and Temasek, DT Capital, Stanford StartX Fund, Nanfeng Capital and other A-round investors participated. Founded in August 2013, Encore has a research and development team of more than 20 scientists in Menlo Park, Silicon Valley, California, USA, and has a clinical research and application promotion team of approximately 45 members in Shanghai, China. The Medical Laboratory is equipped with a high-standard gene amplification laboratory and a high-throughput sequencing platform, focusing on high-throughput sequencing of tumor genes and its application in cancer precision therapy. It is understood that Ankeji was founded by Dr. Ying Kang, Dr. Lin Shengqi and several other founders. Dr. Ying Kang has a strong academic background and rich practical experience in basic medicine, biotechnology, genetic science and business. He graduated from the Second Military Medical University in his early years with a doctorate and post-doctoral experience. In 2000, he transferred to the Institute of Genetics at Fudan University and resigned. He resigned and started his business in 2006. He successfully founded and operated a number of technology companies and trading companies. Chairman and CEO (CEO). Dr. Lin Shengyu has worked as a senior scientist in the Illumina Research Department and has obtained four patents in the United States. He is also a Firefly? The technical inventor is mainly responsible for the team's technology research and development and product development. He is currently the Chief Technology Officer (CTO) of Encore. Calcium Ethoxide CAS No.2914-17-2 Calcium Ethoxide Basic Information
Safety Statements 8-16-26-43
Calcium Ethanoate,Calcium Ethanoate And Ethanol,Calcium Ethanoate Formula,Calcium Ethanoate And Ethanol Reaction,Calcium Ethanoate Balanced Equation,Calcium Ethanoate Bonding Shandong YingLang Chemical Co.,Ltd , https://www.sdylhgtrade.com
CAS: 2914-17-2
MF: C4H10CaO2
MW: 130.2
EINECS: 220-828-8
Mol File: 2914-17-2.mol
Calcium Ethoxide Chemical Properties
Melting point >170°C (dec.)
Safety Information
Risk Statements 11-14-36
